Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

Sandy Wong, MD
Published: Tuesday, Oct 09, 2018



Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

The anti-CD46 antibody is a homegrown compound that was initially studied in a prostate cancer lab at UCSF, explains Wong. Thomas Martin, MD, and Jeffrey Wolf, MD, of UCSF, began studying it in myeloma and has since shown preclinical efficacy. The drug is an antibody against CD46 that is conjugated to the toxin, MMAE, says Wong. By attaching to the surface of CD46, it is internalized by the cell, causing cell death.

CD46 is highly expressed in patients with myeloma, and those who have gain of chromosome 1q as a cytogenetic abnormality have an even higher expression of CD46. In the preclinical studies presented at a prior ASH Annual Meeting, the antibody showed very little efficacy in mice given as a naked antibody, notes Wong. However, when it is given with an antibody that is conjugated to the toxin, the mice survive. Physicians at UCSF are planning a phase I first-in-human trial that is expected to open in the spring of 2019.
SELECTED
LANGUAGE


Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

The anti-CD46 antibody is a homegrown compound that was initially studied in a prostate cancer lab at UCSF, explains Wong. Thomas Martin, MD, and Jeffrey Wolf, MD, of UCSF, began studying it in myeloma and has since shown preclinical efficacy. The drug is an antibody against CD46 that is conjugated to the toxin, MMAE, says Wong. By attaching to the surface of CD46, it is internalized by the cell, causing cell death.

CD46 is highly expressed in patients with myeloma, and those who have gain of chromosome 1q as a cytogenetic abnormality have an even higher expression of CD46. In the preclinical studies presented at a prior ASH Annual Meeting, the antibody showed very little efficacy in mice given as a naked antibody, notes Wong. However, when it is given with an antibody that is conjugated to the toxin, the mice survive. Physicians at UCSF are planning a phase I first-in-human trial that is expected to open in the spring of 2019.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x